Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population-Based Study to Determine the Health System Costs of Using the 21-Gene Assay.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Jan 2018

Mittmann Nicole, Earle Craig C, Cheng Stephanie Y, Julian Jim A, Rahman Farah, Seung Soo Jin, Levine Mark N

Abstract excerpt

Purpose The 21-gene assay Oncotype Dx (Genomic Health, Redwood City, CA) test is used to aid the decision about chemotherapy in patients with hormone receptor-positive breast cancer who received endocrine therapy. Economic studies to support test adoption used decision-analytic models with assumptions and data derived from disparate sources. The objective was to evaluate whether the 21-gene assay test resulted in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Models, Economic
Share to Patient Selection

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Decision-Making

Share to Cost-Benefit Analysis

Share to Databases, Factual

Share to Decision Support Techniques

Share to Drug Costs

Share to Health Care Costs

Source

Identifiers

PMID: 29193984
DOI: 10.1200/JCO.2017.74.2577

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population-Based Study to Determine the Health System Costs of Using the 21-Gene Assay.PMID 29193984Read ↗

Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer.Semantic proximity Read ↗

Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.Semantic proximity Read ↗

Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.Semantic proximity Read ↗

[Impact of the 21-gene assay in decision-making during multidisciplinary breast meeting: A French experience].Semantic proximity Read ↗

The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy.Semantic proximity Read ↗

21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.Semantic proximity Read ↗

The Clinical Impact of 21-Gene Recurrence Score on Treatment Decisions for Patients with Hormone Receptor-Positive Early Breast Cancer in KoreaSemantic proximity Read ↗

Cost-utility analysis of genomic profiling in early breast cancer in ColombiaSemantic proximity Read ↗

Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.Semantic proximity Read ↗

Patterns of 21-gene assay testing and chemotherapy use in black and white breast cancer patients.Semantic proximity Read ↗

Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.Semantic proximity Read ↗

Cost-Effectiveness Analysis of Genomic Profiling in Early Breast Cancer in ColombiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.